HCV Protease Inhibitors

Cat.No. Product Name Information Product Use Citations Product Validations
S3724 Velpatasvir Velpatasvir (GS-5816,VEL) is a second-generation NS5A inhibitor that inhibits hepatitis C viral replication through acting on the crucial "membranous web" that facilitates RNA replication.
mBio, 2023, 10.1128/mbio.01318-23
Front Oncol, 2021, 11:803278
Front Microbiol, 2020, 10:2936
S5403 Ombitasvir (ABT-267) Ombitasvir (ABT-267) is an inhibitor of the HCV non-structural protein 5A with antiviral activity.
Commun Biol, 2022, 5(1):154
Sci Rep, 2021, 11(1):19443
bioRxiv, 2021, 2021.07.21.453274
S5402 Dasabuvir (ABT-333) Dasabuvir (ABT-333) is a non-nucleoside inhibitor of NS5B viral RNA-dependent RNA polymerase that inhibits recombinant NS5B polymerases derived from HCV genotype 1a and 1b clinical isolates with IC50 values between 2.2 and 10.7 nM. It is at least 7,000-fold selective for the inhibition of HCV genotype 1 polymerases over human/mammalian polymerases.
J Virus Erad, 2022, 8(2):100074
mSphere, 2021, 6(6):e0062321
Sci Rep, 2021, 11(1):19443
S5720 Glecaprevir Glecaprevir(ABT-493) is a hepatitis C virus (HCV) nonstructural (NS) protein 3/4A protease inhibitor that targets the the viral RNA replication. It displays IC50 values ranging from 3.5 to 11.3 nM for clinical isolates of HCV genotypes 1a, 1b, 2a, 2b, 3a, 4a, 5a, and 6a.
Cell Rep, 2021, 35(7):109133
Sci Rep, 2021, 11(1):19443
BioRxiv, 2020, 10.1101/2020.12.13.422511
S5394 Tizoxanide Tizoxanide (Desacetyl-nitazoxanide), a thiazolide anti-infective, is active against anaerobic bacteria, protozoa, and a range of viruses in cell culture models, and is currently in phase II clinical development for treating chronic hepatitis C.
Mol Ther, 2024, S1525-0016(24)00340-X
Int J Mol Sci, 2024, 25(8)4413
Virginia Tech, 2023,
S5404 Paritaprevir (ABT-450) ABT-450 (Paritaprevir) is a nonstructural (NS) protein 3/4A protease inhibitor.
Cell Rep, 2021, 35(7):109133
BioRxiv, 2020, 10.1101/2020.12.13.422511
S5307 PSI-6206 (GS-331007) PSI-6206 (RO-2433, GS-331007) is a potent inhibitor of the hepatitis C virus RNA-dependent RNA polymerase, targeting NS5B polymerase.
J Virus Erad, 2022, 8(2):100074
E6045 2'-C-Methylcytidine 2'-C-Methylcytidine (NM107) is a potent and selective inhibitor of Chronic hepatitis C virus (HCV) NS5B polymerase with an EC50 of 1.85 μM in wild-type replicon cells. It also effectively inhibits foot-and-mouth disease virus(FMDV) replication with an EC50 of 6.4 μM. Therefore it is a potent antiviral that targets both viral and host factors, making it a promising option for HCV therapy and a potential prophylactic or therapeutic agent against FMDV outbreaks.
S3395 Tegobuvir Tegobuvir (TGV, GS 333126, GS-9190) is a non-nucleoside inhibitor of HCV RNA replication with proven antiviral activity in HCV-infected patients.
E6002 Ledipasvir D-tartrate Ledipasvir D-tartrate (GS-5885 D-tartrate), the D-tartrate salt form of ledipasvir, is an inhibitor of the HCV NS5A, which is essential for the replication of the virus. It exhibits EC50 of 31 pM against GT1a and 4 pM against GT1b replicons.
S9641 Pibrentasvir (ABT-530) Pibrentasvir (ABT-530) is a novel and pan-genotypic hepatitis C virus (HCV) NS5A inhibitor, with this compound exhibiting EC50 values ranging from 1.4 pM to 5.0 pM against HCV replicons containing NS5A from genotypes 1 to 6.
S5652 Elbasvir Elbasvir (MK8742) is an NS5A inhibitor, preventing hepatitis C viral RNA replication and virion assembly. Median EC50 values range from 0.2 to 3600 pmol/L, based on genotype.
E7964 2'-C-Methyladenosine 2’-C-Methyladenosine is an inhibitor of hepatitis C virus (HCV) replication, with an IC50 of 0.3 µM in Huh-7 cells. It is converted intracellularly to its triphosphate form (2’-C-methyladenosine triphosphate), which acts as a chain terminator and directly inhibits the HCV RNA-dependent RNA polymerase (NS5B) with an IC50 of 1.9 µM in enzymatic assays.
E3597 Herba taxilli Extract Herba Taxilli Extract is extracted from Taxillus sutchuenensis, which can be used as inhibitors of HCV NS3 serine protease.
S2074 Mecarbinate Mecarbinate (Dimecarbin) is a chemical intermediate of arbidol hydrochloride.
S2794 Sofosbuvir Sofosbuvir is a HCV NS5B polymerase inhibitor for the treatment of chronic hepatitis C virus (HCV) infection.
Structure, 2025, S0969-2126(25)00193-5
J Med Virol, 2024, 96(7):e29787
PLoS One, 2024, 19(5):e0303265
Verified customer review of Sofosbuvir
S3800 Lycorine hydrochloride Lycorine (Galanthidine, Amarylline, Narcissine, Licorine), a natural alkaloid extracted from the Amaryllidaceae plant family, has been reported to exhibit a wide range of physiological effects, including the potential effect against cancer. It is an HCV inhibitor with strong activity.
Aging Cell, 2021, e13307
E0097 Mericitabine Mericitabine (RG 7128, R-7128, PSI 6130 diisobutyrate) is a nucleoside inhibitor of the HCV NS5B polymerase that acts as an RNA chain terminator and prevents elongation of RNA transcripts during replication.
E1243 Azvudine Azvudine (RO-0622) is a novel nucleoside reverse transcriptase inhibitor with antiviral activity against human immunodeficiency virus (HIV), hepatitis B virus (HBV) and hepatitis C virus (HCV), potently inhibits HIV-1 (EC50 range 0.03 to 6.92 nM) and HIV-2 (EC50s ranging from 0.018 to 0.025 nM).